Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 2, 2010, Pages 127-136

  Daoussis, Dimitrios ^a   Liossis, Stamatis Nick C ^a   Tsamandas, Athanassios C ^a   Kalogeropoulou, Christina ^a   Kazantzi, Alexandra ^a   Korfiatis, Panagiotis ^a   Yiannopoulos, Georgios ^a   Andonopoulos, Andrew P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

B cells; Fibrosis; ILD; Rituximab; Scleroderma; Systemic sclerosis; Therapy

Indexed keywords

ANTIBIOTIC AGENT; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; DRUG EFFICACY; DRUG PULSE THERAPY; DYSPNEA; EXERCISE TOLERANCE; FOLLOW UP; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; SCLERODERMA, SYSTEMIC; SKIN;

EID: 77957019831     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2009.09.003     Document Type: Article

References (51)

1. Fujimoto M., Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005, 17:746-751.
2. Sato S., Fujimoto M., Hasegawa M., Takehara K., Tedder T.F. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004, 41:1123-1133.
3. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 15 May 2009, [Epub ahead of print].
4. Lafyatis R., Kissin E., York M., Farina G., Viger K., Fritzler M.J., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60:578-583.
5. Smith V.P., Van Praet J.T., Vandooren B.R., Vander C.B., Naeyaert J.M., Decuman S., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 22 Dec 2008, [Epub ahead of print].
6. Korfiatis P., Karahaliou A., Kazantzi A., Kalogeropoulou C., Kostaridou L. Towards quantification of interstitial pneumonia patterns in lung multidetector CT. BioInformatics and BioEngineering. BIBE 2008. 8th IEEE International Conference, Athens, Greece, October 8-10 2008.
7. Siracusa L.D., McGrath R., Ma Q., Moskow J.J., Manne J., Christner P.J., et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996, 6:300-313.
8. Saito S., Kasturi K., Bona C. Genetic and immunologic features associated with scleroderma-like syndrome of TSK mice. Curr Rheumatol Rep 1999, 1:34-37.
9. Saito E., Fujimoto M., Hasegawa M., Komura K., Hamaguchi Y., Kaburagi Y., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
10. Asano N., Fujimoto M., Yazawa N., Shirasawa S., Hasegawa M., Okochi H., et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004, 165:641-650.
11. Hasegawa M., Hamaguchi Y., Yanaba K., Bouaziz J.D., Uchida J., Fujimoto M., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966.
12. Matsushita T., Fujimoto M., Hasegawa M., Matsushita Y., Komura K., Ogawa F., et al. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007, 127:2772-2780.
13. Yoshizaki A., Iwata Y., Komura K., Ogawa F., Hara T., Muroi E., et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008, 172:1650-1663.
14. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
15. Sato S., Fujimoto M., Hasegawa M., Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927.
16. Tsuchiya N., Kuroki K., Fujimoto M., Murakami Y., Tedder T.F., Tokunaga K., et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004, 50:4002-4007.
17. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
18. Sato S., Hayakawa I., Hasegawa M., Fujimoto M., Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003, 120:542-547.
19. Nishijima C., Hayakawa I., Matsushita T., Komura K., Hasegawa M., Takehara K., et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004, 138:357-363.
20. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15:255-273.
21. Svegliati S., Cancello R., Sambo P., Luchetti M., Paroncini P., Orlandini G., et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts J Biol Chem 2005, 280:36474-36482.
22. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
23. Classen J.F., Henrohn D., Rorsman F., Lennartsson J., Lauwerys B.R., Wikstrom G., et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009, 60:1137-1144.
24. Loizos N., Lariccia L., Weiner J., Griffith H., Boin F., Hummers L., et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 2009, 60:1145-1151.
25. Whitfield M.L., Finlay D.R., Murray J.I., Troyanskaya O.G., Chi J.T., Pergamenschikov A., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100:12319-12324.
26. Wollheim F.A. Is rituximab a potential new therapy in systemic sclerosis?: New evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J Clin Rheumatol 2004, 10:155.
27. Lafyatis R., O'Hara C., Feghali-Bostwick C.A., Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007, 56:3167-3168.
28. Harrison N.K., Myers A.R., Corrin B., Soosay G., Dewar A., Black C.M., et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991, 144:706-713.
29. Campbell D.A., Poulter L.W., Janossy G., du Bois R.M. Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax 1985, 40:405-411.
30. Wallace W.A., Howie S.E., Krajewski A.S., Lamb D. The immunological architecture of B-lymphocyte aggregates in cryptogenic fibrosing alveolitis. J Pathol 1996, 178:323-329.
31. Marchal-Somme J., Uzunhan Y., Marchand-Adam S., Valeyre D., Soumelis V., Crestani B., et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006, 176:5735-5739.
32. Atkins S.R., Turesson C., Myers J.L., Tazelaar H.D., Ryu J.H., Matteson E.L., et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006, 54:635-641.
33. Tivol E., Komorowski R., Drobyski W.R. Emergent autoimmunity in graft-versus-host disease. Blood 2005, 105:4885-4891.
34. Daikeler T., Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007, 20:349-360.
35. Perruche S., Marandin A., Kleinclauss F., Angonin R., Fresnay S., Baron M.H., et al. Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation 2006, 81:573-582.
36. Svegliati S., Olivieri A., Campelli N., Luchetti M., Poloni A., Trappolini S., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 110:237-241.
37. Nelson J.L., Furst D.E., Maloney S., Gooley T., Evans P.C., Smith A., et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998, 351:559-562.
38. Murata H., Nakauchi H., Sumida T. Microchimerism in Japanese women patients with systemic sclerosis. Lancet 1999, 354:220.
39. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., Sanders C.J., van den Tweel J.G., Verdonck L.F. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004, 104:2603-2606.
40. Cutler C., Miklos D., Kim H.T., Treister N., Woo S.B., Bienfang D., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
41. Zaja F., Bacigalupo A., Patriarca F., Stanzani M., Van Lint M.T., Fili C., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007, 40:273-277.
42. Carella A.M., Biasco S., Nati S., Congiu A., Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease. Leuk Lymphoma 2007, 48:623-624.
43. Okamoto M., Okano A., Akamatsu S., Ashihara E., Inaba T., Takenaka H., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006, 20:172-173.
44. Ratanatharathorn V., Ayash L., Reynolds C., Silver S., Reddy P., Becker M., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003, 9:505-511.
45. Teshima T., Nagafuji K., Henzan H., Miyamura K., Takase K., Hidaka M., et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 20 Jun 2009, [Epub ahead of print].
46. McGonagle D., Tan A.L., Madden J., Rawstron A.C., Rehman A., Emery P., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008, 47:552-553.
47. Bosello S., De Santis M., Lama G., Spano C., Tolusso B., Sica G., et al. Clinical improvement in systemic slerosis patients treated with anti-CD20 [abstract]. Arthritis Rheum Suppl 2007, 56:494.
48. Lombardi S., Quartuccio L., Franzolini N., Salvin S., Sacco S., Di Poi M., et al. Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis [abstract]. Arthritis Rheum Suppl 2008, 58:S822-S823.
49. Brulhart L., Waldburger J.M., Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006, 65:974-975.
50. Sem M., Molberg O., Lund M.B., Gran J.T. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009, 48:968-971.
51. Calabrese L.H., Molloy E.S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008, 67(Suppl 3):iii64-iii65.